CompletedPhase 4

Effects of Atx and Oros-mph on Executive Functions

43 participantsStarted 2014-02

Plain-language summary

The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).

Who can participate

Age range7 Years – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Combined type ADHD diagnosis was made by a child psychiatrist according to DSM-IV criteria through K-SADS interview with the patient and mother * The Clinical Global Impression Scale (CGI-S) was applied to determine ADHD severity and patients with a CGI-S score≥4 Exclusion Criteria: * Psychological, neurological or psychiatric diseases other than ADHD, * ADHD types other than combined type, * Medication that influences cognitive processes or history of such medication, * WISC-R scores \<80 or \>120

What they're measuring

Effects of Atx and Oros-mph on Executive Functions, measured by Wisconsin Card Sorting Test, Stroop Test TBAG Form and Visual Auditory Digit Span B

Timeframe: 20 weeks

Trial details

NCT IDNCT02352051

SponsorTC Erciyes University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Executive Dysfunction trials